Your browser is no longer supported. Please, upgrade your browser.
Settings
VYNT [NASD]
Vyant Bio, Inc.
Index- P/E- EPS (ttm)-4.77 Insider Own7.90% Shs Outstand28.99M Perf Week-3.38%
Market Cap82.88M Forward P/E- EPS next Y- Insider Trans2.64% Shs Float26.49M Perf Month-23.53%
Income-14.20M PEG- EPS next Q- Inst Own4.90% Short Float0.95% Perf Quarter-12.80%
Sales4.50M P/S18.42 EPS this Y11.00% Inst Trans3.80% Short Ratio0.56 Perf Half Y-23.53%
Book/sh20.07 P/B0.14 EPS next Y- ROA-55.50% Target Price- Perf Year-3.38%
Cash/sh1.14 P/C2.50 EPS next 5Y- ROE-73.00% 52W Range2.11 - 17.50 Perf YTD3.25%
Dividend- P/FCF- EPS past 5Y44.20% ROI-199.60% 52W High-83.66% Beta2.40
Dividend %- Quick Ratio4.60 Sales past 5Y-20.40% Gross Margin33.50% 52W Low35.70% ATR0.19
Employees40 Current Ratio4.70 Sales Q/Q-85.70% Oper. Margin- RSI (14)31.06 Volatility6.18% 6.32%
OptionableNo Debt/Eq0.00 EPS Q/Q-310.50% Profit Margin- Rel Volume0.25 Prev Close2.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume454.41K Price2.86
Recom- SMA20-11.18% SMA50-19.90% SMA200-25.17% Volume112,865 Change-3.05%
Jul-27-21 08:30AM  
Jul-13-21 08:20AM  
May-18-21 06:45AM  
May-17-21 05:15PM  
May-13-21 08:00AM  
May-11-21 04:36PM  
Apr-22-21 08:00AM  
Apr-05-21 04:20PM  
Apr-01-21 05:45PM  
Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boehm MarcusDirectorJul 28Buy2.925,00014,624108,786Jul 28 09:45 PM
Boehm MarcusDirectorMay 28Buy3.685,00018,40098,929Jun 01 05:10 PM
ROBERTS JOHN AChief Executive OfficerMay 26Buy3.557,04124,996312,117May 27 05:31 PM
ROBERTS JOHN AChief Executive OfficerMay 24Buy3.387,44025,147305,076May 27 05:31 PM
FLETCHER R JOHNDirectorMay 24Buy3.3915,30051,83530,300May 24 04:05 PM
FLETCHER R JOHNDirectorMay 21Buy3.3315,00049,94815,000May 24 04:05 PM
Yeh Yung-PingChief Innovation OfficerMay 20Buy3.291,0003,2901,329,602May 21 04:05 PM
LaFrence Andrew D.C.Chief Financial OfficerMay 20Buy3.283,0009,83732,336May 21 04:05 PM